HUTCHMED Highlights Clinical Data for ESMO & ASH Meetings
HUTCHMED will bring a broad slate of oncology and hematology readouts to ESMO Asia (December 5–7, Singapore) and ASH...
Orchestra BioMed Announces New Inducement Grants Under Nasdaq
Orchestra BioMed granted stock options covering 151,250 shares to 12 newly hired employees on November 24 under its 2025...
Bioversys Doses First Subjects in BV100 Phase 1 China Trial
BioVersys has dosed the first healthy volunteer in a China-based Phase 1 study of BV100, an intravenous rifabutin formulation...
Orchestra BioMed Announces New Inducement Grants Under Nasdaq
Orchestra BioMed has issued stock options for 151,250 shares to 12 new hires under a Nasdaq-compliant inducement plan, with...
SciSparc to Acquire Innovative Medical Endoscopy Patents
SciSparc has signed a binding term sheet to acquire a portfolio of patents, trademarks, and know-how from Xylo Technologies,...
Tangram Submits CTA for New Phase 1/2 RNAi MASH Study
Tangram Therapeutics has submitted a Clinical Trial Application to the UK’s MHRA for TGM-312, a GalNAc-conjugated siRNA targeting a...
Nurexone Biologic Q3 2025 Financial Results & Update
Nurexone Biologic reported a busy third quarter: the exosome-focused biotech secured roughly C$4.6 million in fresh capital through accelerated...
PolyPid to Participate in Roth Capital Partners KOL Event
PolyPid will host a virtual KOL event on December 10 to spotlight D-PLEX100, its locally delivered doxycycline depot designed...
Cytomx Therapeutics to Present at Investor Conferences
CytomX Therapeutics will present at two December investor conferences—the Evercore Healthcare Conference on December 2 and the Piper Sandler...
Tangram Submits Phase 1/2 Trial App for MASH Candidate
Tangram Therapeutics has submitted a Clinical Trial Application to the UK MHRA to initiate a Phase 1/2 study of...